Small Patients, Smaller Funding: The Crisis in Pediatric Cancer Funding

Each year, 400,000 children in the United States are diagnosed with cancer. Not tens, not hundreds, but rather hundreds of thousands (World Health Organization, 2025). Cancer is credited as the leading cause of disease-related death among children in the U.S (National Cancer Institute, 2025). Yet, despite this reality, pediatric cancer receives only a fraction of the funding allocated to adult cancers. Childhood cancers receive roughly 4% of the federal budget for cancer research in the U.S., even though the National Cancer Institute has a multibillion dollar budget. This is not because pediatric cancer is insignificant, less urgent or less devastating. Instead, it is because of a funding gap shaped by economics and the structure of medical research.

Of the approximately 400,000 children in the United States diagnosed with cancer each year, approximately 1000 die annually from the disease (Center for Disease Control and Prevention, 2025). The disparity becomes even more striking when you examine the relationship between how much federal funding is received vs the survival rates. Breast cancer alone often receives about 10% in annual funding, while all childhood cancers combined receive only about 4% of federal cancer research funding (NCI, 2025). This resource gap correlates with a significant difference in outcomes: the 5-year survival rate for breast cancer has reached 92%, whereas for childhood cancers, it remains lower at 85% (NCI, 2025). These percentages suggest that survival is not merely dependent on biology and such variables but is also a direct result of financial prioritization. All in all, the success in breast cancer demonstrates that targeted funding accelerates the development of the life-saving screenings and therapies needed to turn a terminal diagnosis into a curable one.

One major contributor to this imbalance lies in market incentives. Pharmaceutical development operates within a profit-driven system, and pediatric cancers represent a smaller patient population, meaning fewer potential consumers for new drugs (American Association for Cancer Research). Developing treatments specifically for children requires specialized dosing, formulations, and extensive safety testing. These additional requirements increase both the cost and complexity of research. As a result, companies often prioritize adult oncology drugs, where the financial return is greater. Consequently, many pediatric treatments today are adapted from adult regimens, some of which were developed decades ago, limiting innovation and effectiveness in the care itself.

Another factor is the division of pediatric cancers. Unlike a single, unified disease category, pediatric cancer encompasses numerous distinct diagnoses, such as leukemia, brain tumors, neuroblastoma, and many others (NCI, 2025). Funding must be divided across these appropriately, making it difficult to build one large, unified advocacy movement. In contrast, adult cancers often benefit from highly recognizable campaigns and sustained public awareness efforts.

Ethical and regulatory challenges further complicate pediatric research. Clinical trials involving children require heightened oversight, including parental consent and additional safety procedures. While these protections are essential, they also increase costs and slow down the research process. 

Addressing the pediatric cancer funding gap requires recognizing that the impact of childhood cancer extends far beyond the initial diagnosis. Treatment may affect developing organs, growth, cognitive function, as well as fertility (NCI, 2025). Even survivors often face long-term complications such as heart damage, secondary cancers, or chronic health conditions (NCI, 2025).  Funding pediatric cancer research is not only about increasing survival rates but also about improving quality of life for decades. 

Closing the funding gap requires awareness, advocacy, and structural change. Increased federal appropriations, incentives for pharmaceutical companies to develop pediatric-specific drugs, and expanded clinical trial networks are all part of the solution (National Pediatric Cancer Foundation). Organizations such as the American Childhood Cancer Organization and the National Pediatric Cancer Foundation continue to push for reform, but long-term change requires sustained public engagement (NPCF).

Pediatric cancer does not receive less funding because it matters less. It receives less funding because of structural priorities that can – and should – be reevaluated. Children deserve the same scientific urgency, the same innovation, and the same national commitment that adults receive. When we invest in pediatric cancer research, we are not only saving lives in the present; we are protecting futures that have barely begun.

Gold should not be quieter than pink. It should shine just as brightly.